1. | dwaysche | |
2. | kirkskraft | |
3. | lieselloveszach | |
4. | 4tokoma4tokoma | |
5. | nlanas2sk051p |
1. | dwaysche | |
2. | kirkskraft | |
3. | lieselloveszach | |
4. | 4tokoma4tokoma | |
5. | nlanas2sk051p |
1. | lieselloveszach 06/28/2018 Cantor Fitzgerald reiterates Buy rating, $42 PT |
2. | 4tokoma4tokoma 02/22/2018 We should be over 40 by now |
3. | lieselloveszach 03/06/2018 Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis® ODT In The Acute Treatment Of Migraine |
4. | lieselloveszach 10/23/2018 Biohaven Receives Authorization to Proceed from FDA and Doses First Subject with BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist |
5. | kirkskraft 02/22/2018 Nice boost |
6. | dwaysche 02/21/2018 Biohaven Announces Exclusive License With Catalent For Zydis® Orally Dissolving Tablet With Small Molecule CGRP Receptor Antagonists |
7. | 4tokoma4tokoma 01/09/2018 Biohaven Announces Positive Results From Bioequivalence Study With Sublingual BHV-0223 Zydis® Orally Dissolving Tablet |
8. | lieselloveszach 06/08/2018 Piper Jaffray sets PT at $48 |
9. | kirkskraft 02/22/2018 Will be in the 40 range soon. |
10. | 4tokoma4tokoma 01/10/2019 Biohaven Announces Acceptance Of Investigational New Drug (IND) Filing For Rimegepant In China |